Fat deposits and their relationship with type 2 diabetes in patients with metabolic syndrome

Abstract

Aim: In Mexico, 18.3% of patients over 20 years of age suffer from type 2 diabetes mellitus (T2DM). Visceral fat has been identified as a risk factor for developing T2DM, considering that its effect depends mainly on the amount, it has been proposed that its location also participates in the genesis of T2DM. This paper aims to analyze whether the location of fatty depots participates in the appearance of T2DM in patients with metabolic syndrome. Methods: A total of 101 patients with metabolic syndrome according to the criteria of the International Diabetes Federation were included. In all of them, epicardial fat (EF) was measured by echocardiography, according to the Iacobelis criteria. Preperitoneal fat (PreF), mesenteric fat (MF), and perirenal fat (PF) were also measured by ultrasound. The statistical methods used were the odds ratio (OR) and Fisher’s exact test. Results: We found a significant association between EF thickness (OR 8.28, 95% CI 2.16–31.70, p = 0.001) and MF (OR 4.27, 95% CI 1.63–11.13, p = 0.0037) with T2DM, 60% of patients with increased PF presented T2DM. Interestingly, no patient with a PF less than 10 mm presented with T2DM. We found no association between PreF and T2DM (OR 0.88, 95% CI 0.32–2.40). Conclusions: The results suggest that the location of adipose tissue plays an important role in the development of T2DM. This may be due to the type of adipocytokines secreted by the various fat deposits and their metabolic effects.

Keywords

epicardial fat / type 2 diabetes mellitus / perirenal fat / mesenteric fat / preperitoneal fat / metabolic syndrome

References

[1] Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023; 65: s163-8.

[2] Campos-Nonato I, Galván-Valencia Ó, Hernández-Barrera L, Oviedo-Solís C, Barquera S. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. Salud Publica Mex. 2023; 65: s238-47.

[3] Lingvay I, Cohen RV, Roux CWl, Sumithran P. Obesity in adults. Lancet. 2024; 404: 972-87.

[4] Rubio-Guerra AF, Cabrera-Miranda LJ, Vargas-Robles H, Maceda-Serrano A, Lozano-Nuevo JJ, Escalante-Acosta BA. Correlation between levels of circulating adipokines and adiponectin/resistin index with carotid intima-media thickness in hypertensive type 2 diabetic patients. Cardiology. 2013; 125: 150-3.

[5] Rubio-Guerra AF, Guerrero-García C, Meneses-Acero I, Maceda-Serrano A, Benítez-Maldonado DR, Vargas-Ayala G, et al. Epicardial fat thickness, but not intraabdominal fat, correlates with intima-media thickness in patients with metabolic syndrome: Epicardial fat and intima-media thickness. Obes Res Clin Pract. 2019; 13: 602-3.

[6] Rubio-Guerra AF, Guerrero-García C, Narváez RJL, Narvaez-Ortiz IG, Montes-Hernández PA, Benítez-Maldonado DR. Correlación entre el grosor de la grasa epicárdica y la velocidad de la onda del pulso. Med Int Méx. 2024; 40: 91-6.

[7] D’Oria R, Genchi VA, Caccioppoli C, Calderoni I, Marrano N, Biondi G, et al. Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System. Int J Mol Sci. 2022; 23: 14296.

[8] Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other Ectopic Fat Depots: The Framingham Heart Study. Am J Med. 2018; 131: 684-92.e12.

[9] Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Lung; Hational Heart, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-5.

[10] Liu KH, Chan YL, Chan WB, Kong WL, Kong MO, Chan JCN. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord. 2003; 27: 1267-73.

[11] Huang N, Mao EW, Hou NN, Liu YP, Han F, Sun XD. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease. World J Diabetes. 2020; 11: 115-25.

[12] Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020; 7: 22.

[13] Wang D, Morton JI, Magliano DJ, Shaw JE. Comparison of subcutaneous, visceral, liver and muscle fat depots in relation to prevalent and incident diabetes. Diabetes Obes Metab. 2025; 27: 6304-13.

[14] Liu KH, Chan YL, Chan JCN, Chan WB. Association of carotid intima-media thickness with mesenteric, preperitoneal and subcutaneous fat thickness. Atherosclerosis. 2005; 179: 299-304.

[15] Karaevren TT, Yorulmaz R, Cerit M, Şendur HN, Kalafat B, Aydın GY, et al. Fatty pancreas disease in newly diagnosed type 2 diabetes patients: a case-control study on relationships with glycemic control and exocrine function. Diabetol Metab Syndr. 2025; 17: 107.

[16] Zheng B, Hu T, Yao J, Zhang Z, Xu Y, Shen H, et al. A Study on the Correlation Between Visceral Adiposity Index, Fatty Liver Index, and Thyroid Dysfunction in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2025; 18: 3553-62.

[17] Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review. Int J Mol Sci. 2024; 25: 8214.

[18] Ghobar F, Tarhini A, Osman Z, Sbeih S, Ghayda RA, Matar P, et al. GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025; 16: 1627909.